SRC and thyroid cancer: Additionally, PF-573228, another FAK inhibitor, interacts with SRC by impeding the formation of the SRC/FAK complex and integrin activation through the inhibition of FAK, resulting in reduced cell proliferation in thyroid cancer [20].